{
    "clinical_study": {
        "@rank": "6673", 
        "arm_group": {
            "arm_group_label": "PET-MR 18F-FACBC", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Prostate cancer is the most frequent cancer in Norwegian men. For optimal treatment,\n      accurate staging of the disease at the time point of diagnosis is important. The objective\n      of this study is to evaluate the diagnostic potential of a combined PET/MR examination for\n      risk assessment and detection of lymph node metastases. The overall aim of the project is to\n      improve the investigators ability to provide individually tailored treatment to prostate\n      cancer patients.\n\n      The study will include 32 men with high-risk prostate cancer, who are eligible for radical\n      prostatectomy. Informed consent is a requirement for inclusion in the study."
        }, 
        "brief_title": "Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status", 
        "completion_date": {
            "#text": "December 2024", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostatic Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Aggression", 
                "Neoplasms", 
                "Prostatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  High-risk prostate cancer according to  EAU guidelines (Gleason score \u22658 and/or PSA\n             \u226520 ng/ml and/or \u2265 cT3a cancer)\n\n          -  Eligibility for the surgical procedure (radical prostatectomy and bilateral pelvic\n             lymph node resection)\n\n        Exclusion Criteria:\n\n          -  Previous treatment (for example TURP or hormone therapy)\n\n          -  Contraindication for the PET/MR examination (including, but not limited to:\n             pacemaker, aneurysm clips, reduced renal function, metal implants, claustrophobia)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02076503", 
            "org_study_id": "2013/1513"
        }, 
        "intervention": [
            {
                "arm_group_label": "PET-MR 18F-FACBC", 
                "intervention_name": "PET-MR 18f-FACBC", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "PET-MR 18F-FACBC", 
                "description": "histopathological classification of co-located dissected lymph nodes", 
                "intervention_name": "histology (gold standard)", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Neoplasm Staging", 
            "Positron-Emission Tomography", 
            "Magnetic Resonance Imaging", 
            "1-amino-3-fluorocyclobutane-1-carboxylic acid"
        ], 
        "lastchanged_date": "April 25, 2014", 
        "location": {
            "contact": {
                "email": "ola.d.sether@ntnu.no", 
                "last_name": "Ola Dalsegg Saether, MD", 
                "phone": "+47 73868370"
            }, 
            "facility": {
                "address": {
                    "city": "Trondheim", 
                    "country": "Norway"
                }, 
                "name": "Dept Urologic Surgery, St Olavs Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Norway"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status", 
        "overall_contact": {
            "email": "ola.d.sether@ntnu.no", 
            "last_name": "Ola Dalsegg Saether, MD", 
            "phone": "+47 73868370"
        }, 
        "overall_contact_backup": {
            "email": "tone.f.bathen@ntnu.no", 
            "last_name": "Tone F Bathen, PhD prof"
        }, 
        "overall_official": {
            "affiliation": "St. Olavs Hospital", 
            "last_name": "Anders Angelsen, prof", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Norway:National Committee for Medical and Health Research Ethics", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Findings on 18FACBC PET/MR images will be compared to histopathology, which is considered the gold standard for evaluation of pelvic lymph node metastases", 
            "measure": "Positive and negative predictive value of 18FACBC PET/MR for detection of lymph node metastases", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02076503"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "St. Olavs Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Norwegian University of Science and Technology", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Norwegian Cancer Society", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "St. Olavs Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}